LIGNEAU; Xavier

Patent Applications and Registrations

Patent applications and USPTO patent grants for LIGNEAU; Xavier.The latest application filed is for "benzimidazole derivatives as dual histamine h1 and histamine h4 receptor ligands".

Company Profile

5.20.22

LIGNEAU; Xavier - SAINT-GREGOIRE FR
LIGNEAU; Xavier - Paris FR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Benzimidazole Derivatives As Dual Histamine H1 And Histamine H4 Receptor Ligands App 20220281839 - BERREBI-BERTRAND; Isabelle ; et al.	2022-09-08
Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands Grant 11,306,069 - Berrebi-Bertrand , et al. April 19, 2	2022-04-19
Novel Combinations Of A H3 Antagonist And A Noradrenaline Reuptake Inhibitor, And The Therapeutical Uses Thereof App 20220079932 - LIGNEAU; Xavier ; et al.	2022-03-17
Combinations of a H3 antagonist and a noradrenaline reuptake inhibitor, and the therapeutical uses thereof Grant 11,229,632 - Ligneau , et al. January 25, 2	2022-01-25
Combination of adrenalin with an antidepressant for use in the treatment of shocks Grant 10,952,987 - Schwartz , et al. March 23, 2	2021-03-23
Novel Combinations Of A H3 Antagonist And A Noradrenaline Reuptake Inhibitor, And The Therapeutical Uses Thereof App 20200030310 - LIGNEAU; Xavier ; et al.	2020-01-30
Benzimidazole Derivatives As Dual Histamine H1 And Histamine H4 Receptor Ligands App 20190144421 - BERREBI-BERTRAND; Isabelle ; et al.	2019-05-16
Combination Of Adrenalin With An Antidepressant For Use In The Treatment Of Shocks App 20190117614 - SCHWARTZ; Jean-Charles ; et al.	2019-04-25
Form of administration of enkephalinase inhibitor Grant 9,439,853 - Julien , et al. September 13, 2	2016-09-13
6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands Grant 9,255,101 - Berrebi-Bertrand , et al. February 9, 2	2016-02-09
A Combination of Adrenaline with an Antidepressant for Use in the Treatment of Shocks App 20150306065 - SCHWARTZ; Jean-Charles ; et al.	2015-10-29
Benzazole derivatives as histamine H4 receptor ligands Grant 9,029,357 - Berrebi-Bertrand , et al. May 12, 2	2015-05-12
Benzazole Derivatives as Histamine H4 Receptor Ligands App 20150004181 - BERREBI-BERTRAND; Isabelle ; et al.	2015-01-01
Carbonylated (aza) cyclohexanes as dopamine D.sub.3 receptor ligands Grant 8,802,678 - Capet , et al. August 12, 2	2014-08-12
Benzazole derivatives as histamine H4 receptor ligands Grant 8,802,664 - Berrebi-Bertrand , et al. August 12, 2	2014-08-12
Form of Administration of Enkephalinase Inhibitor App 20130331423 - Julien; Jean-Stephane ; et al.	2013-12-12
New 6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands App 20130324506 - BERREBI-BERTRAND; Isabelle ; et al.	2013-12-05
Novel (aza)Benzhydryl Ether Derivatives, Their Process of Preparation and Their Use as H4-Receptor Ligands for Therapeutical Applications App 20130324507 - BERREBI-BERTRAND; Isabelle ; et al.	2013-12-05
Benzazole Derivatives as Histamine H4 Receptor Ligands App 20130231329 - Berrebi-Bertrand; Isabelle ; et al.	2013-09-05
Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine Grant 8,354,430 - Raga , et al. January 15, 2	2013-01-15
Monohydrochloride Salt Of 1-[3-[3-(4-chlorophenyl) Propoxy]propyl]-piperidine App 20120289546 - RAGA; Manuel ; et al.	2012-11-15
Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine Grant 8,207,197 - Raga , et al. June 26, 2	2012-06-26
Novel Pharmaceutically Acceptable Salts Of 4-(1h-imidazol-4-ylmethyl)pyridine And Their Therapeutical Uses App 20120129892 - Capet; Marc ; et al.	2012-05-24
Histamine H3-receptor ligands and their therapeutic applications Grant 8,076,329 - Bertrand , et al. December 13, 2	2011-12-13
Non-imidazole Alkylamines As Histamine H3-receptor Ligands And Their Therapeutic Applications App 20110281844 - SCHWARTZ; Jean-Charles ; et al.	2011-11-17
Histamine H.sub.3-receptor ligands and their therapeutic application Grant 8,017,646 - Bertrand , et al. September 13, 2	2011-09-13
Non-imidazole alkylamines as histamine H.sub.3- receptor ligands and their therapeutic applications Grant 7,910,605 - Schwartz , et al. March 22, 2	2011-03-22
Carbonylated (aza) Cyclohexanes As Dopamine D3 Receptor Ligands App 20090286801 - Capet; Marc ; et al.	2009-11-19
Novel Histamine H3-receptor Ligands And Their Therapeutic Applications App 20090111808 - Bertrand; Isabelle ; et al.	2009-04-30
Monohydrochloride Salt of 1-[3-[3-(4-Chlorophenyl) Propoxy] Propyl] -Piperidine App 20080221162 - Raga; Manuel ; et al.	2008-09-11
Histamine H3-Receptor Ligands and Their Therapeutic Application App 20080182876 - Bertrand; Isabelle ; et al.	2008-07-31
Non-imidazole alkylamines as histamine H.sub.3-receptor ligands and their therapeutic applications Grant 7,169,928 - Schwartz , et al. January 30, 2	2007-01-30
Non-imidazole alkylamines as histamine H.sub.3-receptor ligands and their therapeutic applications Grant 7,138,413 - Schwartz , et al. November 21, 2	2006-11-21
Non-imidazole alkylamines as histamine H3- receptor ligands and their therapeutic applications App 20060247223 - Schwartz; Jean-Charles ; et al.	2006-11-02
Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications App 20040220225 - Schwartz, Jean-Charles ; et al.	2004-11-04
Imidazole derivatives as histamine receptor H3 (ANT) agonists Grant 6,248,765 - Schwartz , et al. June 19, 2	2001-06-19

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.